255 related articles for article (PubMed ID: 15146374)
1. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
[TBL] [Abstract][Full Text] [Related]
2. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
[TBL] [Abstract][Full Text] [Related]
3. Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Paniagua JA; López-Miranda J; Pérez-Martínez P; Marín C; Vida JM; Fuentes F; Fernández de la Puebla RA; Pérez-Jiménez F
Diabet Med; 2005 Dec; 22(12):1647-56. PubMed ID: 16401307
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
5. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
[TBL] [Abstract][Full Text] [Related]
6. Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study.
Manuel-Y-Keenoy B; Van Campenhout C; Vertommen J; De Leeuw I
Diabetes Metab Res Rev; 2003; 19(6):478-86. PubMed ID: 14648807
[TBL] [Abstract][Full Text] [Related]
7. Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
De Luis DA; Romero E; Aller R; Izaola O
Clin Nutr; 2000 Oct; 19(5):367-70. PubMed ID: 11031077
[TBL] [Abstract][Full Text] [Related]
8. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Geiss HC; Otto C; Schwandt P; Parhofer KG
Metabolism; 2001 Aug; 50(8):983-8. PubMed ID: 11474489
[TBL] [Abstract][Full Text] [Related]
9. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group.
Betteridge DJ
Int J Clin Pract; 1999 Jun; 53(4):243-50. PubMed ID: 10563066
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
11. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
12. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
14. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome.
Nauck MA; Meier JJ; Wolfersdorff AV; Tillil H; Creutzfeldt W; Köbberling J
Acta Diabetol; 2003 Dec; 40(4):163-72. PubMed ID: 14740275
[TBL] [Abstract][Full Text] [Related]
15. Baseline diene conjugation in LDL lipids from newly diagnosed type 2 diabetic patients.
Gavella M; Lipovac V; Car A; Vucic M
Diabetes Metab; 2002 Nov; 28(5):391-6. PubMed ID: 12461476
[TBL] [Abstract][Full Text] [Related]
16. Cerivastatin.
Cheng-Lai A
Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
[TBL] [Abstract][Full Text] [Related]
17. Postprandial lipaemia in patients with impaired fasting glucose, impaired glucose tolerance and diabetes mellitus.
Madhu SV; Kant S; Srivastava S; Kant R; Sharma SB; Bhadoria DP
Diabetes Res Clin Pract; 2008 Jun; 80(3):380-5. PubMed ID: 18321605
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
[TBL] [Abstract][Full Text] [Related]
19. Treatment of diabetic dyslipoproteinemia.
Steinmetz A
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
[TBL] [Abstract][Full Text] [Related]
20. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
Tran D; Lowy A; Howes JB; Howes LG
Diabetes Obes Metab; 2005 May; 7(3):273-81. PubMed ID: 15811145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
